Carregant...
Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis
Upadacitinib and filgotinib, two JAK1 selective drugs have undergone extensive phase III clinical trials in RA and have demonstrated rapid improvements in disease activity, function and patient reported outcomes. Six global phase III randomized controlled clinical trials (SELECT phase III program) e...
Guardat en:
| Publicat a: | Rheumatology (Oxford) |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8098104/ https://ncbi.nlm.nih.gov/pubmed/33950225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/keaa823 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|